CSPC Pharmaceutical Group disclosed that the FDA cleared an investigational new drug (IND) application for SYH‑2082, a long‑acting GLP‑1/GIP receptor dual‑biased agonist peptide for weight management. The IND allows US clinical trials in people with obesity or overweight plus at least one weight‑related comorbidity, advancing CSPC’s peptide into the competitive incretin field. For developers and investors, the acceptance expands the roster of dual‑agonists entering clinical testing and underlines ongoing global momentum to commercialize next‑generation incretin therapies beyond diabetes into obesity therapeutics.